Immutep Limited (IMMP)
Stock Price:
$1.30 USD
0.02 (1.56%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
63.39M |
| Revenue (ttm) |
5.27M |
| Net Income (ttm) |
-12.92M |
| Shares Out |
38.88M |
| EPS (ttm) |
-0.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$1.30 |
| Previous Close |
$1.28 |
| Change ($) |
0.02 |
| Change (%) |
1.56% |
| Day's Open |
1.28 |
| Day's Range |
1.27 - 1.34 |
| Day's Volume |
223,338 |
| 52-Week Range |
0.53 - 3.10 |
More Stats
| Market Cap |
63.39M |
| Enterprise Value |
57.11M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.88M |
| Float |
36.37M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.40 |
| FCF / Share |
0.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
78,203 |
| Short Ratio |
0.03 |
| Short % of Float |
n/a |
| Beta |
1.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
12.02 |
| PB Ratio |
2.57 |
| Revenue |
5.27M |
| Operating Income |
-12.22M |
| Net Income |
-12.92M |
| Free Cash Flow |
-10.79M |
| Net Cash |
6.29M |
| Net Cash / Share |
0.13 |
| Gross Margin |
100.00% |
| Operating Margin |
-231.62% |
| Profit Margin |
-244.90% |
| FCF Margin |
-204.66% |
| ROA |
-22.01% |
| ROE |
-50.73% |
| ROIC |
-211.40% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.10*
(138.46% upside)
Low
2.00
Current: $1.30
High
4.20
Target: 3.10
*Average 12-month USD price target from 2 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 7.49 | 7.35 | 4.22 | 2.03 | 2.09 | 3.14 | 4.01 | 4.20 | 1.07 | 0.52 |
| Revenue Growth | 1.85% | 74.19% | 108.07% | -3.06% | -33.35% | -21.6% | -4.69% | 294.16% | 103.58% | - |
| Gross Profit | 7.49 | 7.35 | 4.22 | 2.03 | 2.09 | 3.14 | 4.01 | 4.20 | 1.07 | 0.52 |
| Operating Income | -17.35 | -11.69 | -9.35 | -61.47 | -13.93 | -13.33 | -15.11 | -17.27 | -14.13 | -11.01 |
| Net Income | -18.34 | -12.75 | -9.37 | -62.02 | -32.15 | -13.34 | -15.23 | -19.94 | -21.08 | -17.96 |
| Shares Outstanding | 3,026 | 2,080 | 618 | 525 | 369 | 320 | 320 | 320 | - | - |
| Earnings Per Share | -0.01 | -0.01 | - | -0.03 | -0.02 | -0.03 | -0.05 | -0.06 | -0.13 | -0.12 |
| Operating Cash Flow | -15.29 | -7.78 | -8.51 | -11.31 | -7.79 | -14.23 | -16.04 | -19.12 | -12.82 | -6.46 |
| Capital Expenditures | -0.04 | -0.01 | -0.01 | 0.10 | -0.05 | -0.10 | -0.51 | -0.57 | -0.04 | -0.09 |
| Free Cash Flow | -15.33 | -7.79 | -8.51 | -11.21 | -7.84 | -14.33 | -16.55 | -19.69 | -12.87 | -6.56 |
| Cash & Equivalents | 16.57 | 23.48 | 12.24 | 20.88 | 6.76 | 23.20 | 30.02 | 38.04 | 55.92 | 15.64 |
| Total Debt | 7.64 | 6.65 | 5.78 | 5.03 | 1.51 | - | - | - | - | 0.60 |
| Net Cash / Debt | 8.93 | 16.83 | 6.46 | 15.85 | 5.25 | 23.20 | 30.02 | 38.04 | 55.92 | 15.04 |
| Assets | 40.54 | 47.00 | 34.96 | 42.55 | 30.98 | 25.38 | 32.81 | 41.61 | 57.64 | 18.05 |
| Liabilities | 16.15 | 13.48 | 8.43 | 7.24 | 6.29 | 2.79 | 3.57 | 4.45 | 2.54 | 2.21 |
| Book Value | 24.39 | 33.52 | 26.53 | 35.32 | 24.69 | 22.59 | 29.25 | 37.16 | 55.10 | 15.84 |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Immutep Limited |
| CEO |
Marc Voigt |
Stock Information
| Ticker Symbol |
IMMP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMMP |
Description
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.